P2RY12 and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: The P2Y12 platelet inhibitor may have a primary prophylactic role in migraine patients with or without PFO and prevent new-onset MHA after ASDC.